Quarterly report pursuant to Section 13 or 15(d)

NOTE PAYABLE - Additional Information (Detail)

v3.2.0.727
NOTE PAYABLE - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Sep. 30, 2014
Apr. 19, 2013
Note Payable [Line Items]              
Class of Warrant or Right, Exercise Price of Warrants or Rights             $ 0.75
Interest Expense, Debt   $ 2,765 $ 8,294 $ 2,765 $ 8,294    
Debt instrument, unamortized discount   964,060   964,060   $ 955,766  
Loans              
Note Payable [Line Items]              
Notes Payable, Total   $ 944,707   944,707      
2014 Warrant              
Note Payable [Line Items]              
Adjustments to Additional Paid in Capital, Warrant Issued       $ 55,293      
Fair Value Assumptions, Risk Free Interest Rate       2.64%      
Fair Value Assumptions, Expected Dividend Rate       0.00%      
Fair Value Assumptions, Expected Term       10 years      
Fair Value Assumptions, Expected Volatility Rate       114.00%      
Massachusetts Life Sciences Center              
Note Payable [Line Items]              
Subordinated Debt $ 1,000,000            
Debt Instrument, Payment Terms The loan bears interest at a rate of 10% per annum, and will become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period.            
Warrants Issued To Purchase Of Common Stock 145,985            
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.27